Faculty Publications 2021 - 2022

Section of Pulmonary Diseases, Critical Care
and Environmental Medicine
 July 1, 2021 - June 30, 2022

 

RAMSY ABDELGHANI, MD

  1. A Meyer, N Lee, D Thompson, R Abdelghani. Multifactorial, Delayed-Onset Euglycemic Diabetic Ketoacidosis. American Thoracic Society. Pages. A1582-A1582. Publication date May 2022.
  2. Norman M Lee, Christine M Bojanowski, Ramsy A Abdelghani. Arid Airways: Airway Mucosal Injury with Non-humidified Invasive Ventilation. American Journal of Respiratory and Critical Care Medicine. Issue. Ja. May 2022. PMID:35570574

DAVID BECNEL, MD

  1. Pathogenic Role of Epstein–Barr Virus in Lung Cancers. D Becnel, R Abdelghani, A Nanbo, J Avilala, J Kahn, L Li, Z Lin. Viruses 13 (5), 877. https://doi.org/10.3390/v13050877
  2. Michael A. Jantz, Mohamed Omballi, , Bashar N. Alzghoul, Sebastian Fernandez Bussy, David Becnel, Adnan Majid, and Hiren J. Mehta. Utility of bronchoscopic intra-tumoral alcohol injection to restore airway patency. J Thorac Dis. 2021 Aug; 13(8): 4956–4964. PMID: 34527334

CHRISTINE BOJANOWSKI, MD

  1. Lee N, Bojanowski CM, Abdelghani R. Arid Airways: Airway Mucosal Injury with Non-humidified Invasive Ventilation. AJRCCM. Accepted and In Press
  2. Zheng W, LaCourse S, Song B, Singh DK, Khanna M, Olivo J, Stern J, Escudero J, Vergara C, Zhang F, Li S, Wang S, Crammer L, Huang Z, Bojanowski CM, Bao D, Njuguna I, Ziao Y, Warnalwa D, Nguyen D, Yang K, Maleche-Obimbo E, Nguyen N, Zhang L, Phan H, Fan J, Ning B, Li C, Lyon CJ, Gravies EA, John-Steward G, Mitchell CD, Ramsay AJ, Kaushal D, Lianbg R, Perez-Then E, Hu TY. Detection of M. tuberculosis-specific extracellular vesicles in peripheral blood for pediatric TB diagnosis. Nat Biomed Eng. Accepted and In Press
  3. Liao X, Bojanowski CM, Yen A, Kerr KM, Dumouchel J, Auger WR, Madani MM, Pretorius V, Wang H-Y, Yi ES, Lin GY. Inflammatory pseudotumor mimicking chronic pulmonary embolism or pulmonary artery sarcoma: Report of five cases. Pulmonary Circulation. 2022; 12:e12004. https://doi.org/10.1002/pul2.12004
  4. Bojanowski CM, Lu S, Kolls JK.  Mucosal Immunity in Cystic Fibrosis. J Immunol. 2021. 207: 2901-2912; doi: 10.4049/jimmunol.2100424. Invited
  5. Sayed I, Masso-Silva J, Mittal A, Patel A, Lin E, Moshensky A, Shin J, Bojanowski C, Das S, Akuthota P, Crotty Alexander L. Inflammatory phenotype modulation in the respiratory tract and systemic circulation of e-cigarette users: a pilot study. AJP-Lung Cell Mol Physiol. 2021 Oct 27. Doi:10.1152/ajplung.00363.2021. Online ahead of print. PMID: 34704852
  6. Mankowski N, Al-Qurayshi Z, Souza S, Campbell B, Beighley A, Denson J, Mauldin B, Bojanowski C, Friedlander, Zifodya Z. The effect of race, socioeconomic status, and combordity on patients afflicted with COVID-19: A Local Perspective. Ann Epidemiol. 2021 Sep 22; 64: 83-7. Online ahead of print. PMID 34562588
  7. Ning B, Xiao Y, Huang Z, Youngquist BM, Scott JW, Niu A, Bojanowski CM, Zwezdaryk KJ, Saba NS, Fan J, Yin X, Cao J, Lyon CJ, Li C, Roy CJ, Hu TY. Liposome-mediated detection of SARS-CoV-2 RNA-positive extracellular vesicles in plasma. Nat Nanotechnol. 2021 Jul 22. Online ahead of print. PMID: 34294909
  8. Moshensky A, Du M, Shin J, Advani I, Gunge D, Mathew D, Alkolla R, Du A, Javier C, Ma L, Tran A, Nguyen N, Olay J, Nilaad S, Ding J, Najhawan M, Watrous JD, Bojanowski CM, Jain M, Christiani DC, and Crotty Alexander LE.  Vaping induced metabolomic signatures in the circulation of mice are driven by device type, e-liquid, exposure duration and sex.  ERJ Open Res. 2021 Jul; 7 (3). Doi: 10.1183/23120541.00229-2021. eCollection 2021. PMID: 34262972
  9. Weinrich DM, Sivapalasignam S, Norton T, et al. on behalf of the Trial Team. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. N Eng J Med. 2021. 385 (23): e81. PMID: 34587383
  10. O’Brien MP, Forleo-Neto E, Musser BJ, et al. on behalf of the Covid-19 Phase 3 Prevention Trial Team. Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19. N Engl J Med. 2021 Sept 23; 385 (13): 1184-1195. PMID 34347950

Clinical Studies:
Role as PI (Bojanowski):

  1. Randomized Master Protocol for Immune Modulators for Treating COVID-19 (ACTIV-1 IM)
  2. A Prospective Study Evaluating Maternal and Fetal Outcomes in the Era of ModulatorS (MAYFLOWERS
  3. International Prospective Registry for the Diagnosis and Management of Sepsis-Associated Disseminated Intravascular Coagulation
  4. Biospecimen Banking for Future Research in Lung Inflammation and Infection
  5. Impact of Handheld Home Spirometry on Health-Related Anxiety and Health Literacy in Patients with Cystic Fibrosis
  6. Role as Co-I (Bojanowski):
  7. Collection of SARS CoV-2 Secretions and Serum for Countermeasure Development
  8. Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired (REMAP-CAP) Core protocol for COVID-19 patients (REMAP-CAP: covid, REMAP-COVID)
  9. VX-20-121-1102 A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for F508del and a Minimal Function Mutation (F/MF)
  10. Role as Sub-I (Bojanowski):
  11. A Phase3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation
  12. CFF Patient Registry
  13. Pneumonia in the ImmunoCompromised - Use of the Karius Test for the Detection of Undiagnosed Pathogens (PICKUP)
  14. A Phase 2/3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of mavrilimumab (KPL-301) treatment in adult subjects hospitalized with severe COVID-19 pneumonia and hyper-inflammation
  15. A master protocol to test the impact of discontinuing chronic therapies in people with cystic fibrosis on highly effective CFTR modulator therapy (SIMPLIFY)
  16. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis – The ASPEN Study
  17. A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del or Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation Vertex Study Number: VX20-121-103
  18. Human Eosinophilic Disorders in Health and Disease
  19. Multiple Patient Program for Lamprene (clofazimine) for the treatment of Non-Tuberculous Mycobacterial (NTM) Infections - CLAM320B2002M


JOSHUA DENSON, MD

  1. Cervantes-Arslanian AM, Venkata C, Anand P, Burns JD, Ong CJ, LeMahieu AM, Schulte PJ, Singh TD, Rabinstein AA, Deo N, Bansal V, Boman K, Domecq Garces JP, Lee Armaignac D, Christie AB, Melamed RR, Tarabichi Y, Cheruku SR, Khanna AK, Denson JL, Banner-Goodspeed VM, Anderson HL 3rd, Gajic O, Kumar VK, Walkey A, Kashyap R. Neurologic Manifestations of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Hospitalized Patients During the First Year of the COVID-19 Pandemic. Crit Care Explor. 2022 Apr 25;4(4):e0686. doi: 10.1097/CCE.0000000000000686. PMID: 35492258; PMCID: PMC9042584.
  2. Bogojevic M, Bansal V, Pattan V, Singh R, Tekin A, Sharma M, La Nou AT, LeMahieu AM, Hanson AC, Schulte PJ, Deo N, Qamar S, Zec S, Valencia Morales DJ, Perkins N, Kaufman M, Denson JL, Melamed R, Banner-Goodspeed VM, Christie AB, Tarabichi Y, Heavner S, Kumar VK, Walkey AJ, Gajic O, Bhagra S, Rahul Kashyap, Amos Lal, Domecq JP; Society of Critical Care Medicine (SCCM) Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry Investigator Group. Association of Hypothyroidism with Outcomes in Hospitalized Adults with COVID-19: Results from the International SCCM Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry. Clin Endocrinol (Oxf). 2022 Feb 18. doi: 10.1111/cen.14699. Epub ahead of print. PMID: 35180316.
  3. Bjornstad EC, Cutter G, Guru P, Menon S, Aldana I, House S, M Tofil N, St Hill CA, Tarabichi Y, Banner-Goodspeed VM, Christie AB, Mohan SK, Sanghavi D, Mosier JM, Vadgaonkar G, Walkey AJ, Kashyap R, Kumar VK, Bansal V, Boman K, Sharma M, Bogojevic M, Deo N, Retford L, Gajic O, Gist KM; SCCM Discovery VIRUS Investigators Group. SARS-CoV-2 infection increases risk of acute kidney injury in a bimodal age distribution. BMC Nephrol. 2022 Feb 11;23(1):63. doi: 10.1186/s12882-022-02681-2. PMID: 35144572; PMCID: PMC8831033. (*member of the investigative team cited in the appendix of the manuscript).
  4. Wiltz JL, Feehan AK, Molinari NM, Ladva CN, Truman BI, Hall J, Block JP, Rasmussen SA, Denson JL, Trick WE, Weiner MG, Koumans E, Gundlapalli A, Carton TW, Boehmer TK. Racial and Ethnic Disparities in Receipt of Medications for Treatment of COVID-19 - United States, March 2020-August 2021. MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(3):96-102. doi: 10.15585/mmwr.mm7103e1. PMID: 35051133.
  5. O'Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan KC, Musser BJ, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, Hurt CB, Burwen DR, Marovich MA, Brown ER, Heirman I, Davis JD, Turner KC, Ramesh D, Mahmood A, Hooper AT, Hamilton JD, Kim Y, Purcell LA, Baum A, Kyratsous CA, Krainson J, Perez-Perez R, Mohseni R, Kowal B, DiCioccio AT, Geba GP, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD, Weinreich DM; COVID-19 Phase 3 Prevention Trial Team. Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial. JAMA. 2022 Jan 14. doi: 10.1001/jama.2021.24939. Epub ahead of print. PMID: 35029629. (*member of the investigative team cited in the appendix of the manuscript).
  6. Denson JL, Gillet AS, Zu Y, Brown M, Pham T, Yoshida Y, Mauvais-Jarvis F, Douglas IS, Moore M, Tea K, Wetherbie A, Stevens R, Lefante J, Shaffer JG, Armaignac DL, Belden KA, Kaufman M, Heavner SF, Danesh VC, Cheruku SR, St Hill CA, Boman K, Deo N, Bansal V, Kumar VK, Walkey AJ, Kashyap R; Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry Investigator Group. Metabolic Syndrome and Acute Respiratory Distress Syndrome in Hospitalized Patients With COVID-19. JAMA Netw Open. 2021 Dec 1;4(12):e2140568. doi: 10.1001/jamanetworkopen.2021.40568. PMID: 34935924.
  7. Soegaard Ballester JM, Bass GD, Urbani R, Fala G, Patel R, Leri D, Steinkamp JM, Denson JL, Rosin R, Adusumalli S, Hanson CW, Koppel R, Airan-Javia S. A Mobile, Electronic Health Record-Connected Application for Managing Team Workflows in Inpatient Care. Appl Clin Inform. 2021 Oct;12(5):1120-1134. doi: 10.1055/s-0041-1740256. Epub 2021 Dec 22. PMID: 34937103.
  8. Cheruku SR, Barina A, Kershaw CD, Goff K, Reisch J, Hynan LS, Ahmed F, Armaignac DL, Patel L, Belden KA, Kaufman M, Christie AB, Deo N, Bansal V, Boman K, Kumar VK, Walkey A, Kashyap R, Gajic O, Fox AA; Society of Critical Care Medicine Discovery Viral Infection, Respiratory Illness Universal Study VIRUS: COVID-19 Registry Investigator Group. Palliative care consultation and end-of-life outcomes in hospitalized COVID-19 patients. Resuscitation. 2021 Dec 14;170:230-237. doi: 10.1016/j.resuscitation.2021.12.011. Epub ahead of print. PMID: 34920014; PMCID: PMC8669976. (*member of the investigative team cited in the appendix of the manuscript).
  9. Amer M, Kamel AM, Bawazeer M, Maghrabi K, Butt A, Dahhan T, Kseibi E, Khurshid SM, Abujazar M, Alghunaim R, Rabee M, Abualkhair M, Al-Janoubi A, AlFirm AT, Gajic O, Walkey AJ, Mosier JM, Zabolotskikh IB, Gavidia OY, Teruel SY, Bernstein MA, Boman K, Kumar VK, Bansal V, Kashyap R; Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry Investigator Group. Clinical characteristics and outcomes of critically ill mechanically ventilated COVID-19 patients receiving interleukin-6 receptor antagonists and corticosteroid therapy: a preliminary report from a multinational registry. Eur J Med Res. 2021 Oct 2;26(1):117. doi: 10.1186/s40001-021-00591-x. PMID: 34600589; PMCID: PMC8487342. (*member of the investigative team cited in the appendix of the manuscript).
  10. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Xiao J, Hooper AT, Hamilton JD, Musser BJ, Rofail D, Hussein M, Im J, Atmodjo DY, Perry C, Pan C, Mahmood A, Hosain R, Davis JD, Turner KC, Baum A, Kyratsous CA, Kim Y, Cook A, Kampman W, Roque-Guerrero L, Acloque G, Aazami H, Cannon K, Simón-Campos JA, Bocchini JA, Kowal B, DiCioccio AT, Soo Y, Geba GP, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD; Trial Investigators. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. N Engl J Med. 2021 Sep 29. doi: 10.1056/NEJMoa2108163. Epub ahead of print. PMID: 34587383. (*member of the investigative team cited in the appendix of the manuscript).
  11. Mankowski N, Al-Qurayshi Z, Souza S, Campbell B, Beighley A, Denson J, Mauldin B, Bojanowski C, Friedlander P, Zifodya J. The Effect of Race, Socioeconomic Status, and Comorbidity on Patients Afflicted with COVID 19: A Local Perspective. Ann Epidemiol. 2021 Sep 22:S1047-2797(21)00305-7. doi: 10.1016/j.annepidem.2021.09.013. Epub ahead of print. PMID: 34562588; PMCID: PMC8457904.
  12. O'Brien MP, Forleo-Neto E, Musser BJ, Isa F, Chan KC, Sarkar N, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, Hurt CB, Burwen DR, Marovich MA, Hou P, Heirman I, Davis JD, Turner KC, Ramesh D, Mahmood A, Hooper AT, Hamilton JD, Kim Y, Purcell LA, Baum A, Kyratsous CA, Krainson J, Perez-Perez R, Mohseni R, Kowal B, DiCioccio AT, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD, Weinreich DM; Covid-19 Phase 3 Prevention Trial Team. Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19. N Engl J Med. 2021 Sep 23;385(13):1184-1195. doi: 10.1056/NEJMoa2109682. Epub 2021 Aug 4. PMID: 34347950; PMCID: PMC8362593. (*member of the investigative team cited in the appendix of the manuscript).
  13. Hardeman A, Wong T, Denson JL, Postelnicu R, Rojas JC. Evaluation of Health Equity in COVID-19 Vaccine Distribution Plans in the United States. JAMA Netw Open. 2021 Jul 1;4(7):e2115653. doi: 10.1001/jamanetworkopen.2021.15653. PMID: 34213561.

SANDY DITTA, RN

  1. An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease
  2. A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of GKT137831 in Patients with Idiopathic Pulmonary Fibrosis
  3. Analysis of Peptide Splicing Variants as a Biomarker for Progression of Pulmonary Fibrosis
  4. A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis
  5. Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype Prospective Outcomes (ILD-PRO) Registry
  6. Pulmonary Fibrosis Foundation Patient Registry Protocol
  7. Randomized double blinded, placebo-controlled trials to investigate the safety and efficacy of two doses of BI 1015550 PDE4 inhibitor-oral dose twice daily inpatients (1305-0014 for IPF), (1305-0023 for Non-IPF, PF-ILD patients)
  8. A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS

HIMMAT GREWAL, MD

  1. Yuan Zhang, Housne A. Begum, Himmat Grewal, Itziar Etxeandia-Ikobaltzeta, Gian Paolo Morgano, Rasha Khatib, Robby Nieuwlaat, Chengyi Ding, Wojtek Wiercioch, Reem A. Mustafa, Wendy Lim, and Holger J. Sch€unemann. Blood Advances 2021; ‘Cost-effectiveness of diagnostic strategies for venous thromboembolism: Systematic Review’; 19 January 2022.
  2. VIJAIRAM SELVARAJ, MD, MPH; KWAME DAPAAH-AFRIYIE, MD; HIMMAT GREWAL, MD. Cryptic Presentation of Disseminated Cryptococcosis; December 2021.
  3. VIJAIRAM SELVARAJ, MD, MPH; KWAME DAPAAH-AFRIYIE, MD; DENISE FERNANDES, MD; HIMMAT GREWAL, MD. Acute Nephrotic Syndrome and Otosyphilis; February 2022.

CHRISTINE GLYNN, RN

  1. Prospective Treatment Efficacy in IPF Using Genotype for NAC Selection (PRECISIONS) Trial
  2. A Clinical Evaluation of the RheOx Bronchial Rheoplasty System for the Treatment of the Symptoms of Chronic Bronchitis in Adult Patients with COPD
  3. CTBM100C2407 [A prospective observational study in cystic fibrosis patients with chronic respiratory Pseudomonas aeruginosa infection treated with TOBI® Podhaler™ (tobramycin inhalation powder) or other FDA approved inhaled antipseudomonal antibacterial drugs]
  4. A Phase3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation
  5. A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who are Homozygous for F508del, Heterozygous for F08del and a Gating (F/G) or Residual Function (F/RF) Mutation, or have At Least 1 Other Triple Combination Responsive CFTR Mutation and No F508del Mutation
  6. A Prospective Study Evaluating maternal and Fetal Outcomes in the Era of Modulators (MAYFLOWERS)

KARIN HALVORSON, MD

  1. Timothy Amass, MD, ScM1,2; Lauren Jodi Van Scoy, MD3; May Hua, MD, MS4,5; et al. Stress-Related Disorders of Family Members of Patients Admitted to the Intensive Care Unit With COVID-19. JAMA Intern Med. 2022;182(6):624-633. doi:10.1001/jamainternmed.2022.1118. April 15,2022.


ROSS KLINGSBERG, MD

Peer-reviewed publications:

  1. Bojanowski CM, Wilson SM, Klingsberg RC. CFTR modulator therapy improves cystic fibrosis-related diabetes. But how? J Diabetes Complications. 2021 Feb 25.
     

Book Chapters:

  1. Bojanowski CM, Landry M and Klingsberg RC. Care of the Adult with Cystic Fibrosis in Care of the Adult with a Chronic Childhood Condition: A Practical Guide. Pilapil M, DeLaet D, Kuo A, Peacock C and Sharma N (Editors) Springer Publishing. 2022

    Clinical Trials:
  2. A Phase3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation
  3. Cystic Fibrosis Foundation Patient Registry
  4. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis – The ASPEN Study
  5. VX-20-121-102 A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for F508del and a Minimal Function Mutation (F/MF)
  6. A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del or Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation Vertex Study Number: VX20-121-103
  7. Multiple Patient Program for Lamprene (clofazimine) for the treatment of Non-Tuberculous Mycobacterial (NTM) Infections - CLAM320B2002M
  8. Observational Study of Pulmonary Nontuberculous Mycobacterial Disease

JAY KOLLS, MD

  1. Serum Anti-p Jiroveci Glucanase Responses in a Pediatric Cohort
    D Pungan, J Fan, K Zwezdaryk, M Dietrich, J Robinson, G Dai, JK Kolls
    C61. BREAKING THE MOLD, A5752-A5752
  2. IL-22 Binding Protein (IL-22RA2) Is Associated with Chronic Sinopulmonary Infections in Cystic Fibrosis
    CM Bojanowski, K Choi, J Bodnar, S Lee, G Trevejo-Nunez, G Kurland,..
    A62. CYSTIC FIBROSIS AND NON-CF BRONCHIECTASIS: MECHANISTIC INSIGHTS, A1991 …
  3. Identifying Monoclonal Antibodies for Development of Klebsiella Pneumoniae Therapies
    JE Mccombs, JP Hoffmann, JK Kolls
    B31. IMMUNE CELLS AND INFLAMMATORY PATHWAYS DRIVING LUNG INJURY AND …
  4. Single-Cell RNA-seq Revealed T Cell Metabolism as a Target to Tissue-Resident Memory T Cell Contractio, H Yang, JK Kolls
    B31. IMMUNE CELLS AND INFLAMMATORY PATHWAYS DRIVING LUNG INJURY AND …
  5. Vaccine Mediated Lung Tissue Resident Memory T Cells Require IL-1 and CCR2 Signaling to Protect Against K. Pneumoniae Challenge
    JP Hoffmann, N Iwanaga, H Yang, EB Norton, JE Mccombs, JK Kolls
    A101. DEFINING CELLULAR AND MOLECULAR IMMUNE MECHANISMS IN LUNG INFECTIONS …
  6. Interferon-γ promotes monocyte-mediated lung injury during influenza infection
    T Schmit, K Guo, JK Tripathi, Z Wang, B McGregor, M Klomp, ...
    Cell Reports 38 (9), 110456
  7. IL-17RA-signaling in Lgr5+ intestinal stem cells induces expression of transcription factor ATOH1 to promote secretory cell lineage commitment
    X Lin, SJ Gaudino, KK Jang, T Bahadur, A Singh, A Banerjee, M Beaupre, ...
    Immunity 55 (2), 237-253. e8
  8. ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV-2
    N Iwanaga, L Cooper, L Rong, NJ Maness, B Beddingfield, Z Qin, ...
    Iscience 25 (1), 103670
  9. Antibody Responses In Non-Severe SARS-CoV-2 Infections Are Driven By CD4+ T cells and Age.
    AE Murrell, E Eyoh, JG Shaffer, ML Dietrich, IV Trinh, S Bai, CY Zheng, ...medRxiv
  10. Hematopoietic and Lung Platelet Biogenesis as a Prognostic Indicator in Idiopathic Pulmonary Fibrosis (IPF)
    S Saito, CHH Chung, A Jacob, N Nuradin, AE Meyer, T Saito, H Yang, ...medRxiv
  11. Role of the T cell vitamin D receptor in severe COVID-19
    JK Kolls, RF Garr Nature Immunology 23 (1), 5-6
  12. Mucosal Immunity in Cystic Fibrosis
    CM Bojanowski, S Lu, JK Kolls
    The Journal of Immunology 207 (12), 2901-2912
  13. HIV, Pulmonary Infections, and Risk of Chronic Lung Disease among Kenyan Adults
    JS Zifodya, TM Temu, SJ Masyuko, G Nyale, J Kinuthia, ST Page, ...
    Annals of the American Thoracic Society 18 (12), 2090-2093
  14. Surgical stabilization of traumatic rib fractures is associated with reduced readmissions and increased survival
    EA Green, C Guidry, C Harris, P McGrew, R Schroll, M Hussein, E Toraih, ...
    Surgery 170 (6), 1838-1848
  15. Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences
    N Priedigkeit, K Ding, W Horne, JK Kolls, T Du, PC Lucas, JU Blohmer, ...
    Breast Cancer Research 23 (1), 1-14
  16. Exosomes and Microvesicles from Adipose-derived Mesenchymal Stem Cells Protects the Endothelial Glycocalyx From Lipopolysaccharide Injury
    S Taghavi, S Abdullah, F Shaheen, JC Duchesne, S Braun, C Steele, ...
    Journal of the American College of Surgeons 233 (5), e205

JOSEPH LASKY, MD

  1. Joseph A. Lasky, Amy Case, Avraham Unterman, Michael Kreuter, Mary Beth Scholand, Sachin Chaudhary, Lori R. Lofaro, Marla Johnson, Jing Huang, Sangeeta M. Bhorade, Giulia C. Kennedy. The impact of the Envisia Genomic Classifier in the diagnosis and management of patients with idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2021 Dec 10.  
  2. Jamie L Todd, Megan L Neely, Robert Overton, Hillary Mulder, Jesse Roman, Joseph A Lasky, Joao de Andrade, Mridu Gulati, Howard Huang, Thomas B Leonard, Christian Hesslinger, Imre Noth, John A Belperio, Kevin R Flaherty, Scott M Palmer, on behalf of the IPF-PRO Registry investigators. Association of circulating proteins with death or lung transplant in the IPF-PRO Registry cohort. Lung. 2022, Jan. 23.
  3. Kim HJ, Snyder LD, Adegunsoye A, Neely ML, Bender S, White ES, Conoscenti CS, Strek ME; IPF-PRO Registry Investigators. Hospitalizations in patients with idiopathic pulmonary fibrosis. Respir Res. 2021 Sep 30;22(1):257. doi: 10.1186/s12931-021-01851-4.
  4. de Andrade JA, Kulkarni T, Neely ML, Hellkamp AS, Case AH, Culver DA, Guntupalli K, Bender S, Conoscenti CS, Snyder LD; IPF-PRO Registry Investigators. Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Respir Res. 2022 Jan 7;23 (1):3.  
  5. Lee J, White E, Freiheit E, Scholand MB, Strek ME, Podolanczuk AJ, Patel NM; Pulmonary Fibrosis Foundation. Cough-Specific Quality of Life Predicts Disease Progression Among Patients with Interstitial Lung Disease: Data From the Pulmonary Fibrosis Foundation Patient Registry. Chest. 2022 Mar 23: S0012-3692(22)00545-1.
  6. Swaminathan AC, Hellkamp AS, Neely ML, Bender S, Paoletti L, White ES, Palmer SM, Whelan TPM, Dilling DF; Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry investigators. Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry. Ann Am Thorac Soc. 2022 Jun;19(6):981-990
  • Site Director
    • A phase III randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of PRM-151 in patients with idiopathic pulmonary fibrosis. F. Hoffmann-La-Roche Ltd
    • Site Director
  • A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis. United Therapeutics
  • o    Present    Site Director and Chair Performance Committee
  • PRECISIONS (Prospective treatment EffiCacy in IPF using genotype for Nac Selection) study.  This study also aims to distinguish IPF from non-IPF interstitial lung diseases using unbiased combinations of blood transcriptomics, large-scale molecular analysis of blood samples, and proteomics.
  • Site Director
  • A Phase 3, randomized, double-blind, parallel-group, placebo-controlled multi-center study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis.
  • o    Site Director
  • TRAIL1: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease
  • o    A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of GKT137831 in Patients with Idiopathic Pulmonary Fibrosis


ANIL MISHA, PhD., SATHISHA UPPARAHALLI VENKATESHAIAH, Ph.D., CHANDRA SEKHAR YADAVALLI, Ph.D, HEMANTH KUMAR KANDIKATTU, Ph.D.

  1. Anil Mishra, Dewan Majid, Hemanth Kumar Kandikattu, Yadavalli CS, Sathisha Upparahalli Venkateshaiah. Role of IL-18 transformed CD274-expressing eosinophils in promoting airway obstruction in experimental asthma. Allergy journal, Nov, 2021. PMID: 34800294
  2. Sathisha Upparahalli Venkateshaiah, Hemanth Kumar Kandikattu, Yadavalli CS, Anil Mishra. Eosinophils and T cell surface molecule transcript levels in the blood differentiate eosinophilic esophagitis (EoE) from GERD. Int J Basic Clin Immunol. 2021;4(1-2):1-8. PMID: 34557864
  3. Hemanth Kumar Kandikattu, Chandra Sekhar Yadavalli, Sathisha Upparahalli Venkateshaiah, Anil Mishra. Vaccine efficacy in mutant SARS-CoV-2 variants. Int J Cell Biol Physiol. 2021; 4(1-2): 1–12. PMID: 34790972
  4. Sathisha U Venkateshaiah, et al., Blood mRNA levels of T cells and IgE receptors are novel non-invasive biomarkers for eosinophilic esophagitis (EoE), Clin Immunol. 2021;227:108752. PMID: 33945873
  5. Hemanth Kumar Kandikattu, Chandra Sekhar Yadavalli, Sathisha Upparahalli Venkateshaiah, & Anil Mishra. Vaccine efficacy in mutant SARS-CoV-2 variants. Int J Cell Biol Physiol . 2021;4(1-2):1-12. PMID: 34790972
  6. Murli Manohar, Hemanth Kumar Kandikattu, Sathisha Upparahalli Venkateshaiah, Chandra Sekhar Yadavalli & Anil Mishra. Eosinophils in the pathogenesis of pancreatic disorders. Seminars in Semin Immunopathol, 1-12, (2021). PMID: 33783592
  7. Anil Mishra, Hemanth Kumar Kandikattu, Sandeep Kumar, Sathisha Upparahalli Venkateshaiah. An update on available traditional and convalescent plasma (CP) therapies for COVID-19. Int J. Pub. Health Awa. 2021: 4 (1-2) 1-6.
  8. Chandrasekhar Yadavalli, Anil Mishra. Review of: "Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals”. https://doi.org/10.32388/56KNC7.
  9. Hemanth Kumar Kandikattu, Sathisha U Venkateshaiah, et al., Tacrolimus (FK506) treatment protects allergen‐, IL‐5‐ and IL‐13‐induced mucosal eosinophilia. Immunology. 2021;163:220-235. PMID: 33512727
  10. Hemanth K Kandikattu, Murli Manohar, Sathisha U Venkateshaiah et al, Chronic inflammation promotes epithelial-mesenchymal transition-mediated malignant phenotypes and lung injury in experimentally-induced pancreatitis. Life Sci. 2021;278:119640. PMID: 34048812
  11. Sathisha Upparahalli Venkateshaiah, Murali Manohar, Hemanth Kumar Kandikattu, Anil Mishra. Experimental Modeling of Eosinophil-Associated Diseases. Eosinophils (Book Chapter), Methods Mol Biol. 2021;2241:275-291. PMID: 33486743

JAIME PALOMINO, MD

  1. Applicability of the USPSTF Lung Cancer Screening Guidelines in a Predominantly Black Veteran Population. Thomas N. Rusher, MD; Lekha Deere, MD; Albert Jang, MD; Rahul Kamat, MD; and Jaime Palomino, MD. Fed Pract. 2022;39(suppl 2). doi:10.12788/fp.0269

NEREIDA A. PARADA, MD

Clinical trial

  1. CHRONICLE- Astra Zeneca, a longitudinal Prospective Observational Study of the Characteristics, Treatment Patterns and Health Outcomes of Individuals with Severe Asthma in the United States, 234262 AstraZeneca D3250R00023

DEREK POCIASK, Ph.D.

  1. Fatal enhanced respiratory syncytial virus disease in toddlers. Polack FP, Alvarez-Paggi D, Libster R, Caballero MT, Blair RV, Hijano DR, de la Iglesia Niveyro PX, Menendez DR, Gladwell W, Avendano LM, Velozo L, Wanek A, Bergel E, Prince GA, Kleeberger SR, Johnson J, Pociask D, Kolls JK.Sci Transl Med. 2021 Oct 20;13(616):eabj7843. doi: 10.1126/scitranslmed.abj7843. Epub 2021 Oct 20.PMID: 34669442
  2. Interleukin-22 mitigates acute respiratory distress syndrome (ARDS). Taghavi S, Jackson-Weaver O, Abdullah S, Wanek A, Drury R, Packer J, Cotton-Betteridge A, Duchesne J, Pociask D, Kolls J.PLoS One. 2021 Oct 1;16(10):e0254985. doi: 10.1371/journal.pone.0254985. eCollection 2021.PMID: 34597299

CAROL ROCKWELL, RN

  1. Observational Nontuberculous Mycobacteria Clinical Study
  2. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis – The ASPEN Study
  3. Multiple Patient Program for Lamprene (clofazimine) for the treatment of Non-Tuberculous Mycobacterial (NTM) Infections - CLAM320B2002M
  4. Vertex A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for F508del and a Minimal Function Mutation (F/MF)

SHIGEKI SAITO, MD
Publications:

  1. Samant S, Tran HV, Uddo RB, deBoisblanc BP, Saketkoo LA, Saito S, Helmcke FR, Lammi MR. Use of Handheld Ultrasound to Estimate Right Atrial Pressure in a Pulmonary Hypertension Clinic. Ann Am Thorac Soc. 2021 Jul 2. doi: 10.1513/AnnalsATS.202101-092OC. Online ahead of print. PMID: 34214012.
  2. Lammi MR, Samant S, Tran H, Uddo R, Saketkoo LA, Saito S, Helmcke FR, deBoisblanc BP. Jugular venous pressure measured by handheld ultrasound is independently associated with worsening events in pulmonary hypertension patients. Eur Respir J. 2021 Dec 9:2102591. doi: 10.1183/13993003.02591-2021. Online ahead of print. PMID: 34887321
  3. Provisionally accepted- Saito S, Rehan M, Yadav S, Deskin B, Matsunaga Y, Lasky JA, Thannickal VJ. Novel Mediators of Lung Fibrosis Clinical Science 2022.
  4. Preprint - Saito S, Chung CH, Jacob A, Nuradin N, Meyer AE, Saito T, Yang H, Kolls JK, Thannickal VJ, Liu YZ, Lasky JA. Hematopoietic and Lung Platelet Biogenesis as a Prognostic Indicator in Idiopathic Pulmonary Fibrosis (IPF) https://www.medrxiv.org/content/10.1101/2022.04.04.22273424v1

Clinical Studies (Ongoing)
o    An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease.
o    Sponsor: Boehringer Ingelheim
o    Role: Local Principal Investigator
o    Pulmonary Hypertension Association Registry (PHAR)
o    Sponsor: Pulmonary Hypertension Association
o    Role: Sub-investigator
o    OPsumit USers (OPUS) Registry
o    Sponsor: Actelion
o    Role: Sub-investigator
o    Selexipag for pulmonary hypertension associated with sarcoidosis
o    Sponsor: Actelion
o    Role: Sub-investigator
o    A Phase 3, Prospective, Multicenter, Double-blind, Double-dummy, Randomized, Activecontrolled, Parallel-group, Group-sequential, Adaptive, Event-driven Study to Compare Efficacy, Safety, and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension, Followed by an Open-label Treatment

o    Period With Macitentan 75 mg: UNISUS (outcome study assessing a 75 mg dose of macitentan In patients with pulmonary arterial hypertension) trial Sponsor: Actelion
Role: Sub-investigator
o    A Phase 2a, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of RVT-1201 in Patients with Pulmonary Arterial Hypertension
o    Sponsor: Altavant Sciences
o    Role: Sub-investigator

VICTOR THANNICKAL, MD

  1. Qu J, Yang SZ, Zhu Y, Guo T, Thannickal VJ, Zhou Y. Targeting mechanosensitive MDM4 promotes lung fibrosis resolution in aged mice. J Exp Med 2021; 218:e20202033.
  2. Li FJ, Surolia R, Li H, Wang Z, Liu G, Kulkarni T, Massicano AVF, Mobley JA, Mondal S, de Andrade JA, Coonrod SA, Thompson PR, Wille K, Lapi SE, Athar M, Thannickal VJ, Carter AB, Antony VB. Citrullinated vimentin mediates development and progression of lung fibrosis. Sci Transl Med 2021; 13:eaba2927
  3. Jiang C, Liu G, Cai L, Deshane J, Antony V, Thannickal VJ, Liu RM. Divergent Regulation of Alveolar Type 2 Cell and Fibroblast Apoptosis by Plasminogen Activator Inhibitor 1 in Lung Fibrosis. Am J Pathol 2021; 191:1227-1239.
  4. Goliwas KF, Ashraf HM, Wood AM, Wang Y, Hough KP, Bodduluri S, Athar M, Berry JL, Ponnazhagan S, Thannickal VJ, Deshane JS. Extracellular Vesicle Mediated Tumor-Stromal Crosstalk Within an Engineered Lung Cancer Model. Front Oncol 2021; 11:654922.
  5. Bone NB, Becker EJ Jr, Husain M, Jiang S, Zmijewska AA, Park DW, Chacko B, Darley-Usmar V, Grégoire M, Tadie JM, Thannickal VJ, Zmijewski JW. AMPK Activates Parkin Independent Autophagy and Improves Post-Sepsis Immune Defense Against Secondary Bacterial Lung Infections. Sci Rep 2021; 11:12387.
  6. Rehan M, Kurundkar D, Kurundkar AR, Logsdon NJ, Smith SR, Chanda D, Bernard K, Sanders YY, Deshane JS, Dsouza KG, Rangarajan S, Zmijewski JW, Thannickal VJ. Restoration of SIRT3 Gene Expression by Airway Delivery Resolves Age-Associated Persistent Lung Fibrosis in Mice. Nature Aging 2021; 1:205-217.
  7. Chanda D, Rehan M, Smith SR, Dsouza KG, Wang Y, Bernard K, Kurundkar D, Memula V, Kojima K, Mobley JA, Benavides GA, Darley-Usmar V, Kim YI, Zmijewski JW, Deshane JS, De Langhe S, Thannickal VJ. Mesenchymal Stromal Cell Aging Impairs the Self-Organizing Capacity of Lung Alveolar Epithelial Stem Cells. Elife 2021; 10:e68049.
  8. Tousif S, Wang Y, Jackson J, Hough KP, Strenkowski JG, Athar M, Thannickal VJ, McCusker RH, Ponnazhagan S, Deshane JS. Indoleamine 2, 3-Dioxygenase Promotes Aryl Hydrocarbon Receptor-Dependent Differentiation of Regulatory B Cells in Lung Cancer. Front Immunol 2021; 12:747780.
  9. Zhang X, Liu H, Zhou JQ, Krick S, Barnes JW, Thannickal VJ, Sanders YY. Modulation of H4K16Ac Levels Reduces Pro-fibrotic Gene Expression and Mitigates Lung Fibrosis in Aged Mice. Theranostics 2022; 12:530-541.
  10. Wilson AC, Chiles J, Ashish S, Chanda D, Kumar PL, Mobley JA, Neptune ER, Thannickal VJ, McDonald MN. Integrated Bioinformatics Analysis Identifies Established and Novel TGFβ1-Regulated Genes Modulated by Anti-fibrotic Drugs. Sci Rep 2022; 12:3080.
  11. Thannickal VJ. “Myofibroblast Functions in Tissue Repair and Fibrosis: An Introduction” in Myofibroblasts: Methods and Protocols, Boris Hinz and David Lagares, eds., Methods Mol Biol 2021; 2299:9-15.

JERRY ZIFODYA, MD

  1. Zifodya JS, Temu TM, Masyuko S, Nyale G, Nyabiage JM, Nyale G, Kinuthia J, Page S, LaCourse S, Kolls J, Farquhar C, Crothers K, HIV, Pulmonary Infections, and Risk of Chronic Lung Disease among Kenyan Adults, Annals of the American Thoracic Society, 2021; 18(12): 2090-2093. [Original work] PMID: 34237231
  2. Zifodya JS, Triplette M, Shahrir S, Attia EF, Akgun KM, Soo Hoo GW, Wongtrakool C, Rodriguez-Barradas MC, Tate JP, Crothers K, A cross-sectional analysis of diagnosis and management of chronic obstructive pulmonary disease in people living with HIV: Opportunities for improvement, Medicine (Baltimore), 2021; 17, 100(37): e27124 [Original work] PMID: 34664836
  3. Mankowski N, Al-Qurayshi Z, Souza S, Campbell B, Beighley A, Denson J, Mauldin B, Bojanowski C, Friedlander P, Zifodya J, The Effect of Race, Socioeconomic Status, and Comorbidity on Patients Afflicted with COVID 19: A Local Perspective, Ann Epidemiol, 2021; 64: 83-87. [Original work] PMID: 34562588
  4. Mogaka JN, Sharma M, Temu T, Masyuko S, Kinuthia J, Osoti A, Zifodya J, Nakanjako D, Njoroge A, Otedo A, Page S, Farquhar C, Prevalence and factors associated with hypertension among adults with and without HIV in Western Kenya, PLoS ONE 17(1): e0262400 [Original work] PMID: 35007291
  5. Zifodya JS, Ferguson TF, Siggins RW, Brashear MM, Kantrow SP, Nelson S, Shellito JE, Molina PE, Welsh DA, Cross Sectional Analysis of the Effect of Alcohol on Pulmonary Function in a Cohort of Men and Women Living with HIV. Alcohol. 2022 Mar 16: S0741-8329(22)00018-0. doi: 10.1016/j.alcohol.2022.03.001. Epub ahead of print. PMID: 35306109.
  6. Zifodya JS, Crothers K. Tuberculosis, Chronic Obstructive Lung Disease, and Lung Cancer: The Holey Upper Lobe Trinity? Ann Am Thorac Soc. 2022 Apr;19(4):540-